Suraj Kalia
Stock Analyst at Oppenheimer
(3.70)
# 697
Out of 5,182 analysts
92
Total ratings
45.57%
Success rate
9.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Outperform | $132 → $115 | $96.81 | +18.79% | 3 | Apr 17, 2026 | |
| PRCT PROCEPT BioRobotics | Downgrades: Perform | n/a | $25.14 | - | 3 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $150 → $175 | $115.87 | +51.03% | 12 | Feb 25, 2026 | |
| PODD Insulet | Maintains: Outperform | $365 → $300 | $203.73 | +47.25% | 1 | Feb 19, 2026 | |
| ATRC AtriCure | Downgrades: Perform | n/a | $29.72 | - | 8 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $125 → $100 | $64.23 | +55.69% | 1 | Jan 16, 2026 | |
| INSP Inspire Medical Systems | Upgrades: Outperform | $175 | $57.59 | +203.87% | 3 | Dec 8, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $23 → $18 | $12.01 | +49.88% | 7 | Nov 19, 2025 | |
| EW Edwards Lifesciences | Downgrades: Perform | n/a | $80.99 | - | 6 | Oct 8, 2025 | |
| PLSE Pulse Biosciences | Initiates: Outperform | $22 | $23.40 | -5.98% | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $120 | $125.32 | -4.25% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $37.72 | -15.16% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $90 → $93 | $114.36 | -18.68% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.65 | +115.05% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $3.29 | +295.14% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $90.20 | +49.67% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $228.12 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $25.73 | +16.60% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $320 → $200 | $0.54 | +36,664.71% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $74.66 | +29.92% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $21.50 | +30.23% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $5.45 | -17.43% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.71 | +2,152.89% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $469.21 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $2.85 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $18.71 | +434.47% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $63.98 | - | 5 | Sep 12, 2018 |
Abbott Laboratories
Apr 17, 2026
Maintains: Outperform
Price Target: $132 → $115
Current: $96.81
Upside: +18.79%
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Perform
Price Target: n/a
Current: $25.14
Upside: -
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $150 → $175
Current: $115.87
Upside: +51.03%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $365 → $300
Current: $203.73
Upside: +47.25%
AtriCure
Feb 18, 2026
Downgrades: Perform
Price Target: n/a
Current: $29.72
Upside: -
Boston Scientific
Jan 16, 2026
Maintains: Outperform
Price Target: $125 → $100
Current: $64.23
Upside: +55.69%
Inspire Medical Systems
Dec 8, 2025
Upgrades: Outperform
Price Target: $175
Current: $57.59
Upside: +203.87%
Varex Imaging
Nov 19, 2025
Maintains: Outperform
Price Target: $23 → $18
Current: $12.01
Upside: +49.88%
Edwards Lifesciences
Oct 8, 2025
Downgrades: Perform
Price Target: n/a
Current: $80.99
Upside: -
Pulse Biosciences
Jul 7, 2025
Initiates: Outperform
Price Target: $22
Current: $23.40
Upside: -5.98%
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $125.32
Upside: -4.25%
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $37.72
Upside: -15.16%
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $114.36
Upside: -18.68%
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $4.65
Upside: +115.05%
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $3.29
Upside: +295.14%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $90.20
Upside: +49.67%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $228.12
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $25.73
Upside: +16.60%
Jun 23, 2023
Maintains: Outperform
Price Target: $320 → $200
Current: $0.54
Upside: +36,664.71%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $74.66
Upside: +29.92%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $21.50
Upside: +30.23%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $5.45
Upside: -17.43%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $0.71
Upside: +2,152.89%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $469.21
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $2.85
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $18.71
Upside: +434.47%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $63.98
Upside: -